Eton Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-4.6M | $-3.8M | $-936.0K | $-9.0M | $-2.0M | $-28.0M | $-18.3M | $-12.7M |
| Depreciation & Amortization | $4.0M | $1.1M | $901.0K | $66.0K | $155.0K | $347.0K | $283.0K | $63.0K |
| Depreciation | $41.0K | $50.0K | $44.0K | $66.0K | $155.0K | — | — | $51.0K |
| Amortization | $4.0M | $1.1M | $790.0K | $1.6M | $204.0K | $150.0K | $25.0K | — |
| Stock-Based Compensation | $5.5M | $3.2M | $3.1M | $4.2M | $3.4M | $2.6M | $1.9M | $1.9M |
| Net Cash from Operating Activities | $10.5M | $969.0K | $6.8M | $4.8M | $-4.7M | $-22.3M | $-18.0M | $-8.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $333.0K | $26.0K | $0 | $38.0K | $9.0K | $50.0K | $1.1M | $236.0K |
| Business Acquisitions | $0 | $30.0M | $0 | $0 | — | — | — | — |
| Net Cash from Investing Activities | $-333.0K | $-40.0M | $-775.0K | $-2.8M | $-2.6M | $-50.0K | $-1.8M | $-236.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $815.0K | $32.6M | $-957.0K | $-134.0K | $391.0K | $31.6M | $5.2M | $22.0M |
| Net Change in Cash | $11.0M | $-6.5M | $5.1M | $1.9M | $-6.9M | $9.2M | $-14.7M | $13.6M |
| Free Cash Flow | $10.2M | $943.0K | $6.8M | $4.8M | $-4.7M | $-22.4M | $-19.1M | $-8.4M |